bispecific antibody targeting IL-23 and IL-22

Bispecific antibodies targeting IL-23 and IL-22 represent a therapeutic strategy designed to simultaneously inhibit the interleukin-23 (IL-23) and interleukin-22 (IL-22) pathways, which are central to the pathogenesis of psoriasis and other chronic autoimmune skin disorders. A prominent candidate in this class is **CN202**, developed by **Curon Biopharmaceutical**. By blocking IL-23, the antibody inhibits the differentiation and maintenance of pathogenic Th17 cells, while the neutralization of IL-22 prevents the cytokine's direct effects on keratinocytes, such as hyperplasia and the production of inflammatory mediators. Preclinical research, including data presented at the AAD 2026 meeting, has demonstrated that dual blockade of these cytokines provides a synergistic effect, potentially offering superior efficacy compared to monoclonal antibodies targeting either cytokine alone, particularly for patients who are refractory to current IL-23 or IL-17 targeted therapies.

Other names

IL-23/IL-22 bispecific antibodyanti-IL-23/IL-22 bispecific antibodydual IL-23 and IL-22 inhibitor